Results 231 to 240 of about 1,505,630 (287)

Ion Activation Methods for Top‐Down Proteomics

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT Mass spectrometry (MS) has emerged as a premier method used to characterize the sequences of proteins. Top‐down proteomics aims to capture the multiple sources of structural diversity reflected in proteins, such as those that arise from alternative RNA splicing events or the addition of post‐translational modifications. Tandem MS (i.e., MS/MS)
Jada N. Walker, Jennifer S. Brodbelt
wiley   +1 more source

Infections in Patients With Cytokine Release Syndrome/Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy. [PDF]

open access: yesOpen Forum Infect Dis
Gallardo-Pizarro A   +19 more
europepmc   +1 more source

A Prospective Population-Based Study of Chimeric Antigen Receptor T-Cell Therapy for Patients with Diffuse Large B-Cell Lymphoma. [PDF]

open access: yesCurr Oncol
Mozessohn L   +17 more
europepmc   +1 more source

Artificial Intelligence for Identifying Tumor‐Reactive CD8+ T Cells: Biological Principles, Computational Advances, and Future Directions

open access: yesMed Research, EarlyView.
This review details a three‐stage paradigm shift for tumor‐reactive CD8+ T‐cell identification: decoding transcriptomic states, deciphering clonal functional efficacy, and molecular‐level therapeutic TCR design. Addressing translational hurdles and generative AI “scientific blind spots”—such as missing catch bonds—we present a visionary roadmap.
Chao Yang   +4 more
wiley   +1 more source

The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy. [PDF]

open access: yesTher Adv Neurol Disord
Lasocki A   +3 more
europepmc   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

open access: yesMed Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang   +9 more
wiley   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

open access: yesNeuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji   +4 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

open access: yesThe Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi   +8 more
wiley   +1 more source

A novel Chimeric Antigen Receptor (CAR) - strategy to target EGFR<sup>VIII</sup>-mutated glioblastoma cells via macrophages. [PDF]

open access: yesBMC Cancer
Vera K   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy